DOI: https://dx.doi.org/10.18203/2349-3291.ijcp20222126
Published: 2022-08-24

Telegenetics aids the diagnosis of Hunter syndrome caused due to a novel IDS variant in rural India, during COVID-19 pandemic

Shruti Bajaj, Simran Thawani, Gayatri Iyer, Phani N. Setty, Mahesh Kore, Vilas Jadhav

Abstract


The COVID-19 pandemic resulted in an expanded application of telemedicine globally. This enhanced connectivity also opened newer arenas of availability of super-specialty consultations in remote India. The current report highlights the details of a 15-month-old boy from a rural Maharashtra who was diagnosed with Hunter syndrome (HS i.e., mucopolysaccharidosis (MPS-II) via hybrid model of consultation involving telemedicine. The child was first evaluated by a paediatrician in-person, when he was suspected to have one of the MPS subtypes. This was followed by a virtual and an in-person consultation with the clinical geneticist, following which the suspicion for MPS was sharpened further. Exome sequencing identified a novel insertion in IDS gene c.1080_1081insGAATAA, p.Ile360_Phe361insGluTer confirming HS. The mother was identified to be a carrier for this X-linked disorder. The family was counselled about their available reproductive options for the future. The option of enzyme replacement therapy, as a potential lease of life, for improvement of the somatic symptoms, quality and longevity of life, was offered. However, due to the exorbitant lifelong expense that ERT entailed and the lifelong, weekly-injection schedule; the family declined this option. The report highlights the diagnostic journey of a child with HS, which spanned over barely two months following presentation to the specialist. It demonstrates how prudent integration of telemedicine services in resource-limited and pandemic-challenged settings, can help truncate the diagnostic odysseys often borne by patients of rare diseases. It also calls for attention to fill the existing gaps in meaningful healthcare directed towards rare diseases.


Keywords


Telemedicine, Genetic counselling, Enzyme replacement therapy, Exome sequencing, Mucopoly-saccharidosis, Rare diseases

Full Text:

PDF

References


Brown EG, Watts I, Beales ER. Videoconferencing to deliver genetics services: a systematic review of telegenetics in light of the COVID-19 pandemic. Genet Med. 2021;23(8):1438-49.

Mahon SM. Telegenetics: Remote Counseling During the COVID-19 Pandemic. Clin J Oncol Nurs. 2020;24(3):244-8.

Pagliazzi A, Mancano G, Forzano G. Genetic counseling during COVID-19 pandemic: Tuscany experience. Mol Genet Genomic Med. 2020;8(10):e1433.

Rao N, Kanago D, Morris M, et al. Telegenetics: The experience of an Indian center (Centre for Human Genetics) during the COVID-19 pandemic. J Genet Couns. 2021;30(5):1224-32.

Tumulak MJR, Pascua AV, Jover EJM, Guerbo RJ, Canoy GMR, Laurino MY. Genetic counseling in the time of COVID-19: The Philippine experience with telegenetics. J Genet Couns. 2021;30(5):1285-91.

Chou AF, Duncan AR, Hallford G, Kelley DM, Dean LW. Barriers and strategies to integrate medical genetics and primary care in underserved populations: a scoping review. J Community Genet. 2021;12(3):291-309.

Ganapathy K. Telegenomics: Relevance in India. Apollo Med. 2021;18:122-6.

Genetic counselling. Available at: http://www.genetic counselingboardindia.com/certified-counselors.html. Accessed on 20 December 2021.

Cohen SA, Bradbury A, Henderson V, Hoskins K, Bednar E, Arun BK. Genetic counselling and testing in a community setting: quality, access, and efficiency. Am Soc Clin Oncol Educ Book. 2019;39:e34-44.

Westwood RA. Is hybrid telehealth model the next step for private healthcare in India? Health Serv Insights. 2021;14:117-9.

Marshall DA, MacDonald KV, Heidenreich S, Hartley T, Bernier FP, Gillespie MK, et al. The value of diagnostic testing for parents of children with rare genetic diseases. Genet Med. 2019;21(12):2798-806.

Hartley T, Lemire G, Kernohan KD, Howley HE, Adams DR, Boycott KM. New diagnostic approaches for undiagnosed rare genetic diseases. Annu Rev Genomics Hum Genet. 2020;21:351-72.

Basel D, McCarrier J. Ending a diagnostic odyssey: family education, counseling, and response to eventual diagnosis. Pediatr Clin North Am. 2017;64(1):265-72.

Nan H, Park C, Maeng S. Mucopolysaccharidoses I and II: brief review of therapeutic options and supportive/palliative therapies. Biomed Res Int. 2020;2020:240-8

Muranjan M, Karande S. Enzyme replacement therapy in India: Lessons and insights. J Postgrad Med. 2018;64(4):195-9.

National policy for rare disease 2021. Available at: https://main.mohfw.gov.in/sites/default/files/Final. pdf. Accessed on 20 December 2021.